Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07594431

Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.

Unblinded, randomized study of 5-fraction LATTICE radiotherapy (20 Gy with an SIB to 66.7 Gy in 5 fractions) versus moderately dose-escalated palliative radiation (25 Gy in 5 fractions)

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Metastases Metastatic Cancer Neoplasm Metastasis Neoplasms Neoplastic Processes Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

12 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

80 patients with confirmed metastatic tumor (>2.5 cm in short axis) will be enrolled, all ≥ 12 years of age with ECOG ≤ 2. All genders and races will be included.

Inclusion criteria

  • Histologically, cytologically, or radiographically confirmed diagnosis of metastatic cancer
  • One to two metastases in non-brain sites that are amenable to LATTICE radiotherapy: >2.5 cm in short axis (dimension on axial imaging that is perpendicular to the longest dimension); bone metastasis can be included if the extraosseous component is >2.5 cm in short axis
  • Age ≥12
  • ECOG Performance Status 0-2
  • For patients age 12-16, Lansky Play-Performance score 50-100
  • Negative serum or urine pregnancy test within 2 weeks prior to enrollment of people of childbearing potential
  • All patients and/or their parents or legal guardians must sign a written informed consent. For any child less than 18 years of age, assent must also be obtained in addition to parental or legal guardian consent.

Exclusion criteria

  • Prior radiation therapy to the tumor to be treated
  • Active pregnancy
  • Diseases that place the patient at high risk of radiation complications including lupus, scleroderma, Li Fraumeni syndrome
  • The tumor to be treated is from a hematologic malignancy such as lymphoma or myeloma

Treatment and study plan

Lattice Radiotherapy

Radiation

5-fraction LATTICE radiotherapy delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.

Standard radiotherapy

Radiation

Standard radiotherapy delivered to 25 Gy in 5 fractions.

Primary outcomes

  1. Percent Tumor Volume Reduction Following Radiotherapy

    Time frame: 90 +/- 20 days following radiotherapy

    Radiographic response defined as percent tumor volume reduction 90 +/- 20 days following radiotherapy

Study contacts

Contact information is provided by the study sponsor or research team.

Camellia Djebroun

CONTACT

[email protected]

650-736-5564

Jamie Wang

CONTACT

[email protected]

650-497-4354

Sponsors and collaborators

Lead sponsor

Stanford University

Other

Registry information

Official study title

A Randomized Phase II Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
May 18, 2026
Registry last updated
May 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.